ADICET BIO INC (ACET)       13.92  +0.13 (+0.94%)

13.92  +0.13 (+0.94%)

US0070021086 - Common Stock

ADICET BIO INC13.92

NASDAQ:ACET (9/27/2022, 9:17:36 AM)+0.13 (+0.94%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-10 2022-08-10/bmo Earnings (Next) 11-08 2022-11-08
Ins Owners 0.93% Inst Owners 95%
Market Cap 557.23M Shares 40.03M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 87.5
IPO 01-26 2018-01-26

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACET Daily chart

Company Profile

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2018-01-26. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL), to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its lead product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is under Phase I study for the treatment of Non-Hodgkin's Lymphoma. Its pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, it is engaged in discovery and preclinical stage activities of its pipeline of product candidates for both hematological malignancies and solid tumors.

Company Info

ADICET BIO INC

200 Berkeley Street, 19Th Floor

Boston MASSACHUSETTS 02116

P: 16174822333.0

CEO: Chen Schor

Employees: 86

Website: https://www.adicetbio.com/

ACET News

News Image20 days ago - Adicet Bio, Inc.Adicet Bio to Present at Upcoming Investor ConferencesNews Imagea month ago - Adicet Bio, Inc.Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)News Imagea month ago - Market News VideoNotable Two Hundred Day Moving Average Cross - ACETNews Image2 months ago - Adicet Bio, Inc.Adicet Reports Second Quarter 2022 Financial Results and Provides Business UpdatesNews Image2 months ago - InvestorPlace7 Cheap Biotech Stocks to Buy Now

These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.

News Image2 months ago - Adicet Bio, Inc.Adicet Bio to Present at Upcoming Investor Conferences

ACET Twits

Here you can normally see the latest stock twits on ACET, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example